In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS.
In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.
The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth
The neonates will be diagnosed with NRDS or NARDS
The neonates will be at least administrated one dose of surfactant
major congenital anomalies
chromosomal abnormalities
upper respiratory tract abnormalities
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lead sponsor
Children's Hospital of Chongqing Medical University
Sponsor institution
Children's Hospital of Chongqing Medical University
Collaborator